CD274 and pneumonia: Although the anticancer activity of PD-1 and PD-L1 inhibitors is exciting, such immunotherapy is not effective for all patients, and a meta-analysis shows that patients who receive PD-1 / PD-L1 inhibitors have a higher risk of rash, thyroid dysfunction, pruritus, pneumonia and colitis29–31.